« January 2006 | Main | April 2006 »

Mar30
Potential Market for Novel Allergy Medications
Gloria Gamat March 30, 2006
Know More:

First, I wanna thank a long time friend and colleague, Ruth Schaffer (now a "colleague" in the science blogosphere) for guest blogging here at The PharmVoice.

I myself am dependent on Claritin to relieve me of my itchy symptoms and am fairly satisifed with the results. My son uses Fenistil drops and so far, it works. But according to the results of a survey released last week by The Asthma and Allergy Foundation of America (AAFA),

  • 31% are not satisfied with their current allergy prescription
  • 60% are interested in finding a new drug
  • 55% said that their current medication does not relieve their allergy symptoms for a long enough period of time
  • 44% said their medication doesn't provide quick enough relief

So many numbers. All it boils down to is the fact that a significant number of allergy sufferers are not satisfied with their medications, whether oral or nasal.

A lucrative market for pharmaceutical companies, I say, including manufacturers of generic allergy medications.


Ruth Schaffer writes at The Biotech Weblog, Allergizer and Let's Visit Asia.
Posted at 7:33 PM | Permalink | Comments
Mar30
Anthrim(TM), Anthrax Antibody Therapeutic, Passes Phase 1 Human Clinical Trial
Gloria Gamat March 30, 2006
AnthrimTM , ElusysTherapeutics Inc.'s fast-tracked anthrax antibody therapeutic has successfully passed its human clinical trial designed to determine its safety and tolerability in healthy volunteers, when administered with or without the antibiotic Ciprofloxacin®. "The Anthim Phase 1 study, AH-101, has... Continue Reading
Posted at 5:22 AM | Permalink | Comments
Big Pharma Bad
Gloria Gamat March 30, 2006
First of all, I wanna thank a colleague at B5media, Dr. Hsien-Hsien Lei for agreeing to guest blog here at The PharmVoice:       Of all the evil in the world, pharmaceutical companies rank amongst the worst.  Agree or... Continue Reading
Posted at 2:37 AM | Permalink | Comments
Mar29
Calypte Biomed Corp’s Rapid HIV Test Kits, Approved in Kenya
Gloria Gamat March 29, 2006
Calypte Biomedical Corporation’s rapid tests for HIV: Calypte Aware™ HIV-1/2 BSP (blood) and Aware™ HIV-1/2 OMT (oral fluid) has been issued a Kenyan National Public Health Laboratory Services (NPHLS) notification of registration and approval. These HIV test kits are... Continue Reading
Posted at 1:00 AM | Permalink | Comments
Ranbaxy Lab Ltd. Acquires Allen S.p.A., a GSK-Italy Division
Gloria Gamat March 29, 2006
Ranbaxy Laboratories Limited is among the top ten generic pharmaceutical companies and ’s largest pharmaceutical company. Recently, the company announced its acquisition of the unbranded generic business of Allen S.p.A. (a division of GlaxoSmithKline (GSK) Italy through Ranbaxy’s Italian subsidiary... Continue Reading
Posted at 12:59 AM | Permalink | Comments
Mar28
Santarus Inc.’s ZEGERID® with Magnesium Hydroxide Chewable Tablets Received USFDA NDA Approval
Gloria Gamat March 28, 2006
Santarus Inc. is a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders. Yesterday the company received a USFDA approval for its New Drug application (NDA) of its product ZEGERID® with Magnesium Hydroxide (omeprazole/sodium bicarbonate/magnesium hydroxide) Chewable Tablets... Continue Reading
Posted at 12:57 AM | Permalink | Comments
Cymbalta® Significantly Reduces Core Anxiety Symptoms of Generalized Anxiety Disorder, Study Says
Gloria Gamat March 28, 2006
In a study of some 500 patients, the safety and efficacy of the antidepressant Cymbalta® on the core anxiety symptoms in patients with generalized anxiety disorder was evaluated. Findings of the said study showed that Cymbalta® significantly reduced core anxiety... Continue Reading
Posted at 12:30 AM | Permalink | Comments
Additional Doses of Risperdal® Now Available By Prescription
Gloria Gamat March 28, 2006
Risperdal® is one of the most prescribed antipsychotic drug and Risperdal® M-TAB® is its fast dissolving form. Now, two additional doses (3 mg and 4 mg) of Risperdal® (risperidone) is now available for prescription to schizophrenia or bipolar mania patients.... Continue Reading
Posted at 12:18 AM | Permalink | Comments
Mar26
Ranexa™, Now Available in U.S. Pharmacies
Gloria Gamat March 26, 2006
CV Therapeutic Inc.’s Ranexa™ is now available in pharmacies and is now being promoted to cardiology specialists in the United States. Ranexa™ (ranolazine extended-release tablets) is approved as second-line treatment for chronic angina and has antianginal and anti-ischemic effects that... Continue Reading
Posted at 11:53 PM | Permalink | Comments
Upcoming Conference: Strategic Pharmaceutical Marketing
Gloria Gamat March 26, 2006
What: Strategic Pharmaceutical Marketing:Practical Tools and Techniques for Creative and Compliant Marketing in a Complex Regulatory Environment When: March 30-31, 2006 Where: Princeton Marriott Hotel & Conference Center at Forrestal, Princeton, NJ    ... Continue Reading
Posted at 11:28 PM | Permalink | Comments
Avicena Group Inc.’s HD-02, Designated Orphan Drug for HD by USFDA
Gloria Gamat March 26, 2006
HD-02, the Avicena Group Inc.’s proprietary drug candidate for the treatment of Huntington's disease (HD) recently received a USFDA orphan drug designation. In the journal Neurology, the company published the positive results of its Phase I/II data for HD-02. The... Continue Reading
Posted at 8:54 PM | Permalink | Comments
PXD101 and Velcade® (bortezomib), Into Phase Ib/II Clinical Trial for Multiple Myeloma (MM)
Gloria Gamat March 26, 2006
Multiple myeloma is a deadly form of blood cancer, characterized by excessive numbers of abnormal plasma cells in the bone marrow and the overproduction of abnormal immunoglobulins.   Recently, CuraGen Corporation and TopoTarget A/S initiated the patient dosing in... Continue Reading
Posted at 8:26 PM | Permalink | Comments
Mar23
Levitra® Found Effective against ED in Hypertensive Men
Gloria Gamat March 23, 2006
Along with diabetes and high cholesterol, hypertension is one of the major risk factor that affects erectile dysfunction (ED), affecting 29.4 million men in the alone. Moreover, many blood-pressure-lowering medications (beta-blockers and diuretics) may adversely affect erectile function.   Levitra®... Continue Reading
Posted at 11:07 PM | Permalink | Comments
Raloxifene: Osteoporosis Drug, Now on Phase II Clinical Trial for Prostate Cancer
Gloria Gamat March 23, 2006
Raloxifene is a drug commonly used to treat osteoporosis has been recently to be a potential treatment against prostate cancer by researchers at Cedars-Sinai Medical Center . Since Raloxifene is a drug already on the market, researchers were able to... Continue Reading
Posted at 10:18 PM | Permalink | Comments
Patent Case Settlement on Plavix®
Gloria Gamat March 23, 2006
The makers of Plavix®, Sanofi-Aventis and Bristol-Myers Squibb have tentatively settled a patent dispute on the drug. Plavix®, an anti-clotting agent is the world’s second-best selling drug have been settled to be generically manufactured by Apotex, a Canadian generic drug... Continue Reading
Posted at 2:32 AM | Permalink | Comments
Mar22
Helix BioMedix, Inc. and Grant Industries’ Granactive™ Acne Solution, Passes Human Panel Test
Gloria Gamat March 22, 2006
The collaboration between Helix BioMedix, Inc. (developer of bioactive peptides) and Grant Industries (private developer,manufacturer and marketer of cosmetic, textile, and performance specialty chemicals resulted to an acne blend for use in over-the-counter acne products: acne solution Granactive™, a combination... Continue Reading
Posted at 3:03 AM | Permalink | Comments
Schering-Plough and PTC Therapeutics Collaborating on Development of PTC's Preclinical Hepatitis C Compounds
Gloria Gamat March 22, 2006
On March 20, Schering-Plough Corporation and PTC Therapeutics, Inc. announced their collaboration and licensing agreement for the development of PTC's preclinical compounds for the oral treatment of hepatitis C virus (HCV) infection and other viral diseases. "The goal of this... Continue Reading
Posted at 2:45 AM | Permalink | Comments
Eli Lilly & Co. and Biosite® Inc. Enters Collaboration on Clinical Trial Using Tailored Xigris® Therapy
Gloria Gamat March 22, 2006
Eli Lilly & Company and Biosite® Incorporated announced their collaboration on a clinical trial employing a tailored therapy strategy for Lilly's severe sepsis drug, Xigris® (drotrecogin alfa [activated]).  The trial will investigate the use of a multipurpose biomarker (Protein C)... Continue Reading
Posted at 1:35 AM | Permalink | Comments
Monsanto’s Posilac® bST, FDA Approved for Manufacture in Augusta
Gloria Gamat March 22, 2006
Monsanto Company’s Posilac® has been FDA approved for its full production at the company’s Augusta, facilities. Posilac® bST (bovine somatotropin) is a milk production enhancer that serves as an important tool to help dairy producers improve the efficiency and profitability... Continue Reading
Posted at 1:03 AM | Permalink | Comments
Sunesis Pharma Inc.’s SNS-595 Enters Phase II Clinical Trial for Small Lung Cancer
Gloria Gamat March 22, 2006
The Phase II clinical trial of Sunesis Pharmaceuticals, Inc.’s SNS-595 just started. The clinical trial will examine the safety and efficacy of SNS-595 as a second-line agent in patients with small cell lung cancer who have failed first-line therapy. SNS-595... Continue Reading
Posted at 12:37 AM | Permalink | Comments
Mar21
Medidur™, Novel Treatment for DME, DSMB Recommended to Continue Phase 3 Clinical Trial
Gloria Gamat March 21, 2006
Alimera Sciences Inc. and pSivida Limited’s Medidur™ is a tiny, injectable device to deliver fluocinolone acetonide (a corticosteroid) to the retina as a treatment for diabetic macular edema (DME) has just been recommended by the Data Safety Monitoring Board (DSMB)... Continue Reading
Posted at 1:44 AM | Permalink | Comments
Despite Vioxx®, Merck is Venturing into Pain Drugs
Gloria Gamat March 21, 2006
It was a big blow to Merck & Company when Vioxx® was withdrawn from the market due to increased risk of heart attack. Not in the attempt to replace Vioxx® but in identifying pain as one of the nine medical... Continue Reading
Posted at 1:15 AM | Permalink | Comments
Mar20
Topical Meeting Driven by Pandemic Threat
Gloria Gamat March 20, 2006
What: Vaccine Production: Potential Engineering Approaches to a Pandemic   When: April 10-11, 2006   Where: Case Western Reserve University , Severance Hall, Cleveland, Ohio. A meeting organized by The National Academy of Engineering, the Institute of Medicine, and... Continue Reading
Posted at 3:42 AM | Permalink | Comments
DelSite’s GelVac® system, Novel Avian Flu Vaccine to be presented at the World Vaccine Conference
Gloria Gamat March 20, 2006
With the daily treat of an avian flu pandemic as suggested by the world’s health experts, the unique GelVac® system, developed by DelSite Biotechnologies (a subsidiary of Carrington Laboratories) could be the solution to deliver more vaccines to more people,... Continue Reading
Posted at 3:23 AM | Permalink | Comments
Senate Supports Prescription Drug Bargaining
Gloria Gamat March 20, 2006
On Wednesday the (U.S.) Senate gave approval granting the federal government the power to bargain with pharmaceutical manufacturers for lower prices under the Medicare Prescription Drug Program. Since January 1 of this year, Medicare began offering drug benefits to seniors... Continue Reading
Posted at 2:53 AM | Permalink | Comments
Mar17
Phase 3 Clinical Trial of Oral Temsirolimus in Women with Metastatic Breast Cancer, Terminated by Wyeth due to IDMC Review
Gloria Gamat March 17, 2006
HORIZON is the phase 3 clinical trial program of Wyeth's investigational drug temsirolimus oral tablets in combination with letrozole (Femaraâ) (a currently approved breast cancer therapy) for first-line use in postmenopausal women with hormone-receptor positive metastatic breast cancer. Wyeth Pharmaceuticals... Continue Reading
Posted at 11:15 PM | Permalink | Comments
Yaz®: First Oral Contraceptive to Offer Drospirenone in a 24-day, Active-Pill Regimen, FDA Approved
Gloria Gamat March 17, 2006
Schering AG, Germany’s U.S. affiliate Berlex, Inc. just announced the  USFDA approval of Yaz® (3 mg drospirenone/20 mcg ethinyl estradiol), a new monophasic oral contraceptive (OC) and the first pill to combine 20 mcg of ethinyl estradiol with the innovative... Continue Reading
Posted at 10:48 PM | Permalink | Comments
Extended-Cycle Oral Contraceptive SEASONIQUE™: No Additional Clinical Data Required for Approval, Says Barr Pharma Inc.
Gloria Gamat March 17, 2006
Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for SEASONIQUE™ (levonorgestrel/ethinyl estradiol tablets 0.15 mg/0.03 mg and ethinyl estradiol tablets 0.01 mg) extended-cycle oral contraceptive, doesn’t need additional clinical data for USFDA approval as announced by Barr Pharmaceuticals, Inc. which will... Continue Reading
Posted at 10:26 PM | Permalink | Comments
Cholesterol-Lowering Atorvastatin, Effective MS Therapy
Gloria Gamat March 17, 2006
The cholesterol-lowering drug, atorvastatin has been found to be an effective therapy for preventing the progression and reversing the severity of multiple sclerosis (MS) according to Scientists at the University of California , San Francisco and Stanford University Medical Center... Continue Reading
Posted at 3:36 AM | Permalink | Comments
EntreMed Inc., Made Strong by New 2ME2 Patent
Gloria Gamat March 17, 2006
EntreMed, Inc. has been granted a U.S. Patent No. 7,012,070 covering methods of treatment for a broad range of indications with its lead clinical-stage compound, 2-methoxyestradiol (2ME2). Patent No. 7,012,070 which is entitled “Estrogenic Compounds as Anti-Mitotic Agents,” includes claims... Continue Reading
Posted at 1:21 AM | Permalink | Comments
Advexin® Passes Phase I/II Clinical Trial in Advanced Esophageal Cancer Patients
Gloria Gamat March 17, 2006
Intratumoral administration of multiple Advexin® doses in advanced esophageal cancer patients has shown to be safe, feasible and clinically active; giving Introgen Therapeutics, Inc. enough reason to announce the publication of the positive data from the said Phase I/II clinical... Continue Reading
Posted at 12:59 AM | Permalink | Comments
Mar16
Warning to Patients on Plavix® Medication
Gloria Gamat March 16, 2006
Recent media reports on Plavix® may be misinterpreted by patients with coronary stents and other conditions*, causing these patients to inappropriately stop taking the anti-clotting drug clopidogrel (Plavix®). In any case, patients taking Plavix® for any reason must discuss the... Continue Reading
Posted at 10:31 PM | Permalink | Comments
Old Generic Drug, New Weapon against Pandemic
Gloria Gamat March 16, 2006
Amantadine (1-aminoadamantane, sold as Symmetrel®) is a generic drug for treatment of seasonal flu that has been created in the 1970s. Today, it might become the new weapon along with Tamiflu in the onset of a pandemic. Research evidence is... Continue Reading
Posted at 2:50 AM | Permalink | Comments
Nastech Pharma Inc. & Novo Nordisk A/S, In Agreement
Gloria Gamat March 16, 2006
A leader in developing therapeutics using advanced molecular biology-based drug delivery technologies, Nastech Pharmaceuticals Company Inc. announced yesterday that it has entered into a multi-compound, feasibility study agreement with Novo Nordisk A/S with respect to certain Novo Nordisk therapeutic compounds.... Continue Reading
Posted at 12:21 AM | Permalink | Comments
Mar15
Oxytrex™ Shows Promise for Further Development, Says Pain Therapeutics
Gloria Gamat March 15, 2006
Oxytrex™ is an investigational drug, a strong opioid painkiller with minimal physical dependence intended for patients with severe chronic pain. Pain Therapeutics today announced that it will present results from prior Phase III studies evaluating the safety, efficacy and minimal... Continue Reading
Posted at 10:19 PM | Permalink | Comments
Phenoptin™ Showed Positive Results from Phase 3 Clinical Study
Gloria Gamat March 15, 2006
Phenylketonuria (PKU) is a genetic disorder that is characterized by an inability of the body to utilize the essential amino acid, phenylalanine. Phenoptin™ (sapropterin dihydrochloride) is an investigational oral small molecule for the treatment of phenylketonuria (PKU). Today, BioMarin Pharmaceutical... Continue Reading
Posted at 9:59 PM | Permalink | Comments
Provenge®, Novel Vaccine for Prostate Cancer: The Market Awaits
Gloria Gamat March 15, 2006
Prostate cancer is the third most common cancer in the world. Diosynth Biotechnology has been awarded by Dendreon with a long –term contract to supply its novel vaccine for prostate cancer in anticipation of the USFDA approval. The novel vaccine... Continue Reading
Posted at 9:21 PM | Permalink | Comments
Wanted: Guest Bloggers
Gloria Gamat March 15, 2006
Do you think you can blog here at The PharmVoice? If you think you can, Know More Media is welcoming guest bloggers (maximum of 5 bloggers, not necessarily 1 entry per blogger) on this blog for the duration 27 March to... Continue Reading
Posted at 8:41 PM | Permalink | Comments
Mar13
ZoMaxx™ Drug-Eluting Coronary Stent’s First Human Clinical Trial Showed Positive Results
Gloria Gamat March 13, 2006
ZoMaxx™, Abbott’s investigational Drug-Eluting Coronary Stent System demonstrated 100% procedural success, no major adverse cardiac events and minimal late lumen loss (vessel diameter loss) in the first human clinical trial (4-month period) conducted to evaluate the safety and performance of... Continue Reading
Posted at 10:14 PM | Permalink | Comments
Abbott to Market FREESTYLE® FREEDOM™ Blood Glucose Monitoring System, FDA Granted Clearance
Gloria Gamat March 13, 2006
The USFDA granted a 510K clearance to Abbott Diabetes Care to market the company’s FreeStyle® Freedom™ blood glucose monitoring system for consumer use. FreeStyle® Freedom™ requires the smallest blood sample size (0.3 micro liter) among all blood glucose monitoring product... Continue Reading
Posted at 9:15 PM | Permalink | Comments
Plavix®’s Safety in Question
Gloria Gamat March 13, 2006
A major clinical study found that the drug Plavix®, may cause dangerous bleeding in patients who take it along with aspirin to prevent heart attack. The results of the study which will be published in the New England Journal of Medicine... Continue Reading
Posted at 8:43 PM | Permalink | Comments
Drug Delivery Partnerships 2006
Gloria Gamat March 13, 2006
What: Drug Delivery Partnerships 2006 One of Europe 's leading meetings that bring together decision makers working in the field of drug delivery. The meeting provides executives from pharmaceutical, biotech, drug delivery and specialty pharma companies to network and strike... Continue Reading
Posted at 2:25 AM | Permalink | Comments
Dentonin® Passes Phase 2 Clinical Trial
Gloria Gamat March 13, 2006
Dentonin® or AC-100  is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells that can stimulate the formation of new dentin (the hard tissue of teeth that protects the tooth pulp and supports... Continue Reading
Posted at 12:48 AM | Permalink | Comments
Ranexa® Shipments Ongoing
Gloria Gamat March 13, 2006
Ranexa™ (ranolazine extended-release tablets) was approved by USDA for marketing on January 27, 2005 and is now being shipped to pharmaceutical wholesalers. CV Therapeutics, the drug’s manufacturer is anticipating that Ranexa™ will be available in pharmacies by the end of... Continue Reading
Posted at 12:24 AM | Permalink | Comments
DAYTRANA, ADHD Transdermal Patch, Under FDA Class I Resubmission
Gloria Gamat March 13, 2006
DAYTRANA (methylphenidate transdermal system (MTS)) is an investigational transdermal patch formulation for methylphenidate designed for once-daily use to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 to 12 years. In December 2005, it received an NDA approvable letter... Continue Reading
Posted at 12:04 AM | Permalink | Comments
Mar12
USDA Grants Approvable Letter to NPS Pharma Inc. for PREOS® NDA
Gloria Gamat March 12, 2006
The USFDA deemed NPS Pharmaceuticals, Inc’s NDA (new drug application) for PREOS® (parathyroid hormone [rDNA origin] for injection) approvable. PREOS® is a recombinant human parathyroid hormone (PTH) that reduces the risk of first and subsequent vertebral fractures in post-menopausal women.... Continue Reading
Posted at 11:46 PM | Permalink | Comments
Mar11
Phase 2 Clinical Trial of Corgentech’s ALGRX 4975 Showed Significant Decreased Pain from Tendonitis
Gloria Gamat March 11, 2006
The Phase 2 clinical trial of ALGRX 4975 is showing positive results according to Corgentech Inc. ALGRX 4975 is one of three non-opioid pain management drug candidates the company is developing for pain relief of patients with elbow tendonitis. Corgentech... Continue Reading
Posted at 2:44 AM | Permalink | Comments
Mar10
U.S. is World Leader in Important New Drugs Introduction, Study Says
Gloria Gamat March 10, 2006
According to a study led by a Duke University economist, the U.S. pharmaceutical industry has become the world leader in introducing important new drugs since 1993. U.S. firms introduced 48 percent of first-in-class or novel drugs, 52 percent of biotech... Continue Reading
Posted at 11:44 PM | Permalink | Comments
Iomai Corp. Received Second Installation of NIH Fund for IS Patch against Flu
Gloria Gamat March 10, 2006
Biopharmaceutical company, Iomai Corp. received a $1.4 Million award from the National Institutes of Health (NIH) for the continued development of its immunostimulant (IS) needle-free patch to extend the availability of existing stocks of influenza vaccine in the case of... Continue Reading
Posted at 11:34 PM | Permalink | Comments
Cardium Therapeutics, Inc. Acquired InnerCool Therapies, Inc.
Gloria Gamat March 10, 2006
InnerCool Therapies, Inc., a San Diego-based medical technology company focused on the emerging field of therapeutic hypothermia has been recently acquired by Cardium Therapeutics, Inc. InnerCool Therapies, Inc. is a developer, manufacturer and marketer of endovascular, catheter-based therapeutic systems designed... Continue Reading
Posted at 3:08 AM | Permalink | Comments
BioCryst Pharma, Inc. Enters Peramivir Phase I Clinical Trial
Gloria Gamat March 10, 2006
BioCryst Pharmaceuticals, Inc. entered into phase I clinical trial of Peramivir, the company's lead influenza neuraminidase inhibitor, to determine the pharmacokinetics and safety of single and multiple doses of an intravenous (IV) formulation of the drug in healthy volunteers. This... Continue Reading
Posted at 2:23 AM | Permalink | Comments
Novel Nicotine Addiction Vaccine NicVAX® Received US FDA Fast Tract Designation
Gloria Gamat March 10, 2006
NicVAX® (Nicotine Conjugate Vaccine), Nabi Biopharmaceutical’s novel, innovative and proprietary investigational vaccine under development to treat nicotine addiction and prevent smoking relapse has received Fast Track Designation from the U.S. FDA. Fast Track regulations facilitate the development of products that... Continue Reading
Posted at 1:14 AM | Permalink | Comments
APP Received Two Tentative USFDA Approvals for Ondansetron Injection, Generic Zofran®
Gloria Gamat March 10, 2006
The American Pharmaceutical Partners, Inc. received two tentative approvals from the U.S. FDA for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Injection, USP (single-dose and multiple-dose vials), GlaxoSmithKline's Zofran® Injection’s generic version. APP expects to receive the final approval... Continue Reading
Posted at 12:35 AM | Permalink | Comments
Mar 9
Remicade®, First EU approved Biologic Treatment for Ulcerative Colitis (UC)
Gloria Gamat March 9, 2006
The European Commisions granted approval to Remicade® (infliximab) as treatment of moderately to severely active ulcerative colitis (UC) in patients who had inadequate response to conventional therapy (including corticosteroids and 6-MP or AZA) or who are intolerant to or have... Continue Reading
Posted at 11:39 PM | Permalink | Comments
Bristol-Myers Squibb Co., to build U.S. Manufacturing Facility
Gloria Gamat March 9, 2006
During its March 7 regular meeting, the Bristol-Myers Squibb Company’s Board of Directors approved a capital expenditure in the amount of $660 million for the construction of a large-scale multi-product bulk biologics manufacturing facility in the .   Pharmaceuticals President... Continue Reading
Posted at 2:31 AM | Permalink | Comments
Erbitux®, First and Only FDA Approved Treatment for Head and Neck Cancer
Gloria Gamat March 9, 2006
The US FDA approval of Erbitux® (Cetuximab) (an IgG1 monoclonal antibody, for use in the treatment of squamous cell carcinoma of the head and neck) was recently announced by ImClone Systems Incorporated and Bristol-Myers Squibb Company.   The first and... Continue Reading
Posted at 2:12 AM | Permalink | Comments
Mar 8
Perrigo Co. Bagged FDA Approval to Manufacture and Market Generic Loprox®
Gloria Gamat March 8, 2006
As announced earlier, the US FDA gave Perrigo Company approval to manufacture and market Ciclopirox Olamine Cream USP 0.77%, the generic version of Medicis Pharmaceutical manufactured Loprox® Cream 0.77%, an anti-fungal medication indicated for the topical treatment of skin infections:... Continue Reading
Posted at 3:24 AM | Permalink | Comments
Mar 7
Twinject®, 2 dose-Epinephrine against Anaphylaxis
Gloria Gamat March 7, 2006
Anaphylaxis is a severe, life-threatening systemic allergic reaction. Verus Pharmaceuticals, Inc., announced study results supporting the potential need for two doses of epinephrine to treat anaphylaxis. The study, “Factors Affecting the Use of Automatic Epinephrine Injectors”, was presented today as... Continue Reading
Posted at 11:30 PM | Permalink | Comments
Miraxion®, Potential Anti-Melancholic Depression Drug Says Amarin Corp plc
Gloria Gamat March 7, 2006
The most severe form among depressive disorders is melancholic depression. It is more prevalent among hospitalized depression patients than among those in the community. Affected persons lack pleasure in almost all activities and do not react to pleasurable stimulation. They... Continue Reading
Posted at 11:13 PM | Permalink | Comments
Baxter HealthCare Corp Enters Phase II Adult Stem Cell Trial in U.S. CMI Patients
Gloria Gamat March 7, 2006
CMI (chronic myocardial ischemia) is a severe form of coronary artery disease. It is a serious heart condition that involves narrowing of coronary arteries which results in limited blood flow to the heart and is affecting hundreds of thousands of... Continue Reading
Posted at 10:21 PM | Permalink | Comments
Doctors Warned Not to Base Prescription Solely on Drug Promo Brochures
Gloria Gamat March 7, 2006
A study recently published in the open access journal BMC Family Practice found that promotional brochures produced by pharmaceutical companies to promote drugs to doctors don’t always present accurate data. Eventhough small differences were found, authors of the study still... Continue Reading
Posted at 8:59 PM | Permalink | Comments
Generic Flonase Make it to the Market
Gloria Gamat March 7, 2006
Fluticasone propionate nasal spray, manufactured by Roxane Laboratories of Columbus, OH, is the first generic version of the brand name drug Flonase approved by FDA. Flonase is an anti-inflammatory nasal spray used to treat the nasal symptoms of indoor and... Continue Reading
Posted at 8:31 PM | Permalink | Comments
Novartis Seeks Approval for Exforge®, a 2-in-1 Blood Pressure-Lowering Tablet
Gloria Gamat March 7, 2006
Two of the leading blood pressure-lowering tablets: amlodipine and valsartan; have been combined by Novartis in one tablet called Exforge® which has been shown in clinical trials (involving more than 5,000 patients) to provide powerful blood pressure control with excellent... Continue Reading
Posted at 8:03 PM | Permalink | Comments
New DNA Recognition Method Offers New Drug Design
Gloria Gamat March 7, 2006
Scientists from Barcelona and Birmingham have discovered a new way that drugs can attach themselves to DNA which led to the discovery of a synthetic drug agent that targets and binds to the centre of a 3-way junction in the... Continue Reading
Posted at 7:29 PM | Permalink | Comments
Collaboration Against Infectious Diseases
Gloria Gamat March 7, 2006
With the aim of discovering novel therapeutics for infectious diseases, Graffinity announced its second collaboration with Mutabilis. These days, the anti-infective market is facing serious challenges due to the growing resistance by infective microorganisms to almost all available products that... Continue Reading
Posted at 12:17 AM | Permalink | Comments
Mar 6
End Essential Drug Tariffs, Save Lives
Gloria Gamat March 6, 2006
The Word Health Organization reported in 2005 that many countries burdened with such diseases as HIV/AIDS, tuberculosis and malaria are still imposing tariffs on imports of medicines and medical devices. On Monday, trade officials said that the US, Switzerland and... Continue Reading
Posted at 9:04 PM | Permalink | Comments
Botox® Cosmetic, More Efficient and Longer Lasting than Dysport®
Gloria Gamat March 6, 2006
At the recommended dosage, Botox Cosmetic (botulinum toxin type A) also known as VISTABEL or VISTABEX in Europe proved to be more efficient and tolerable in treating moderate to severe glabellar lines (the vertical frowns between the brows) compared to... Continue Reading
Posted at 8:48 PM | Permalink | Comments
Cowen & Co. 26th Annual Health Care Conference
Gloria Gamat March 6, 2006
What: Cowen & Co. 26th Annual Health Care Conference When: Monday, March 6th, at 2:20 pm ET Where:Province Town Meeting Room,3rd floor, Boston Marriott Copley Place ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of... Continue Reading
Posted at 12:48 AM | Permalink | Comments
FDA Guidelines to Expedite Development of Seasonal and Pandemic Flu Vaccines